AbCellera Biologics
Latest round
- Series B
Last raised
- May 2020
Total raised
- $115M
Investors
- 7
About AbCellera Biologics
AbCellera Biologics Inc.Founded in 2012 in Vancouver, Canada, AbCellera Biologics Inc. specializes in developing innovative antibody-based therapeutics.15 million shares at USD 20 per share on the Nasdaq. The firm has completed 11 deals to date.AbCellera specializes in the development of innovative antibody-based therapeutics, leveraging its advanced technology platform that integrates biology, computation, and engineering. The company’s primary focus is on creating first-in-class and best-in-class monoclonal antibodies for a range of health conditions, including endocrine disorders and autoimmune diseases. Notable products in their pipeline include ABCL635, an antibody targeting NK3R for the treatment of vasomotor symptoms associated with menopause, and ABCL575, which targets OX40L for moderate-to-severe atopic dermatitis.31 mn. The company’s revenue model is primarily driven by partnerships with biopharmaceutical companies, which engage the firm for its expertise in antibody discovery and development. Transactions typically occur through collaborative agreements where clients fund specific projects, thereby sharing in the potential commercialization of the resulting therapeutics. The structure of these agreements may include milestone payments linked to the achievement of development stages, along with royalties on future sales of the developed products.AbCellera plans to enhance its product pipeline with new therapeutics in development, aiming for significant advancements in treatment options for various health conditions. The company is focused on expanding its reach into additional global markets, particularly in Europe and Asia, with initiatives expected to ramp up over the next few years. This investment will facilitate the launch and development of new products in their pipeline, which are anticipated to play a crucial role in the company's future trajectory.
Who invested in AbCellera Biologics
7 investors across 2 rounds
See all investors in AbCellera Biologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about AbCellera Biologics
Who invested in AbCellera Biologics?
AbCellera Biologics has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AbCellera Biologics raised?
AbCellera Biologics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did AbCellera Biologics last raise money?
AbCellera Biologics's most recent round on record is a Series B, in May 2020.
What does AbCellera Biologics do?
AbCellera Biologics is a biotechnology company.
Where is AbCellera Biologics headquartered?
AbCellera Biologics is headquartered in Vancouver, Canada.
Which VCs invest in companies like AbCellera Biologics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at AbCellera Biologics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like AbCellera Biologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.